Lewis N R, Scott B B
Department of Gastroenterology, Lincoln County Hospital, Lincoln, UK.
Aliment Pharmacol Ther. 2006 Jul 1;24(1):47-54. doi: 10.1111/j.1365-2036.2006.02967.x.
With the appreciation of the high prevalence of coeliac disease there is increasing use of serology in screening asymptomatic people and testing those with suggestive features.
To compare the sensitivities and specificities of the endomysial antibody and the tissue transglutaminase antibody tests.
Using electronic databases a search was made for relevant papers using the terms tissue transglutaminase and endomysial antibody.
Both the endomysial antibody and tissue transglutaminase antibody have very high sensitivities (93% for both) and specificities (>99% and >98% respectively) for the diagnosis of typical coeliac disease with villous atrophy. Human recombinant tissue transglutaminase performs much better than guinea pig tissue transglutaminase. Review of studies comparing endomysial antibody with human recombinant tissue transglutaminase antibody shows that endomysial antibody more often has a higher specificity and human recombinant tissue transglutaminase antibody more often has a higher sensitivity.
The human recombinant tissue transglutaminase antibody is the preferred test for screening asymptomatic people and for excluding coeliac disease in symptomatic individuals with a low pretest probability (i.e. <25%) for coeliac disease. Furthermore, it has a number of practical and financial advantages. If the pretest probability is >25%, biopsy is preferred as the post-test probability of coeliac disease with a negative test is still >2%.
随着对乳糜泻高患病率的认识不断提高,血清学检测在筛查无症状人群以及对具有提示性特征的人群进行检测中的应用越来越广泛。
比较肌内膜抗体和组织转谷氨酰胺酶抗体检测的敏感性和特异性。
利用电子数据库,使用“组织转谷氨酰胺酶”和“肌内膜抗体”等术语搜索相关论文。
肌内膜抗体和组织转谷氨酰胺酶抗体对诊断伴有绒毛萎缩的典型乳糜泻均具有很高的敏感性(两者均为93%)和特异性(分别>99%和>98%)。人重组组织转谷氨酰胺酶的性能比豚鼠组织转谷氨酰胺酶好得多。对比较肌内膜抗体与人重组组织转谷氨酰胺酶抗体的研究进行综述发现,肌内膜抗体更常具有较高的特异性,而人重组组织转谷氨酰胺酶抗体更常具有较高的敏感性。
人重组组织转谷氨酰胺酶抗体是筛查无症状人群以及排除乳糜泻患病前概率较低(即<25%)的有症状个体患乳糜泻的首选检测方法。此外,它还具有许多实际和经济优势。如果患病前概率>25%,则首选活检,因为检测结果为阴性时乳糜泻的患病后概率仍>2%。